|
PROWESS [39]
|
Pre-infusion log IL-6, APACHE II score
|
127/547 (23.2)
|
Hazard ratio = 1.16 (95% CI = 1.07 to 1.26); P <0.001
|
| | | |
Hazard ratio = 1.23 (95% CI = 1.09 to 1.39); P <0.001
|
|
NORASEPT II [54]
|
Plasma IL-6
|
112/537 (20)
|
Not significant
|
| |
Plasma TNFα
| |
Not significant
|
| |
Soluble TNFα receptor type I
| |
Higher in SSAKI; P <0.0001
|
| |
Soluble TNFα receptor type II
| |
Higher in SSAKI; P <0.0001
|
|
PICARD [40]
|
Plasma TNFα
|
34/97 (35)
|
Higher in patients with SSAKI (P = 0.001) than those without sepsis
|
| |
Plasma IL-6
| |
Not significant
|
|
Hoste and colleagues [55]
|
APACHE II score
|
30/185 (16.2)
|
APACHE II score higher (P = 0.002)
|
| |
pH <7.35
| |
OR for developing ARF = 6.25 (95% CI = 1.92 to 20.4); P = 0.002
|
| |
Serum creatinine >1 mg/dl
| |
OR for developing ARF = 7.56 (95% CI = 2.16 to 26.5); P = 0.002
|
|
Martensson and colleagues [56]
|
Peak serum NGAL
|
18/45 (40)
|
Not significant in SSAKI vs. septic shock without AKI
|
| |
Peak urine NGAL
| |
Higher in SSAKI than septic shock without AKI (P <0.05)
|
|
Shapiro and colleagues [43]
|
Emergency room plasma NGAL
|
24/661 (3.6)
|
NGAL >150: sensitivity = 96% and specificity = 51%
|
|
de Geus and colleagues [42]
|
Serum NGAL
|
171/632 (27)
|
OR of developing ARF = 1.7
|
| |
Urine NGAL
| |
OR of developing ARF = 1.42
|
| |
Sepsis
| |
OR of developing ARF = 9.15
|
